News

GKAs have the potential to differentiate from other anti-diabetic agents by exerting two potentially beneficial actions: promoting insulin secretion and decreasing glucose production by the liver. As a

BEMA buprenorphine is being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in

U.S. Patent No. 8,673,292, titled "Pure Populations of Astrocyte Restricted Percursor Cells and Methods for Isolation and Use Thereof," covers the astrocyte family of neural cells of the

The agreement is expected to allow ORGS to advance its manufacturing (GMP) process from lab scale to clinical scale as it prepares for Phase I and Phase II

Both, PSP and CBD represent diseases of the central nervous system and are collectively called as tauopathies, and for which no FDA approved therapies exist. The Phase I

Andexanet alfa is Portola’s investigational Factor Xa inhibitor antidote and edoxaban is Daiichi Sankyo’s Factor Xa inhibitor. The two firms have signed original collaboration agreement in June 2013

The trial of RGN-259 (a Thymosin Beta 4-based preservative-free eye drop) is based on data secured from a 72-patient, double-masked, placebo-controlled trial sponsored by RegeneRx and conducted by

Daklinza is a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), while Sunvepra is a NS3/4A protease inhibitor. Currently there are no treatment options for this disease in

GSK noted that trametinib has not showed clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. The EU approval is based on results from